Mavenclad®

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis

Trial Timeline

Jun 20, 2018 → Nov 12, 2021

About Mavenclad®

Mavenclad® is a approved stage product being developed by Merck for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03369665. Target conditions include Multiple Sclerosis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (4)

NCT IDPhaseStatus
NCT04783935ApprovedCompleted
NCT04776213ApprovedCompleted
NCT03369665ApprovedCompleted
NCT03364036ApprovedCompleted